Neurotrophic Keratitis - Pipeline Insight, 2025

This “Neurotrophic Keratitis - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Neurotrophic Keratitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Neurotrophic Keratitis: Understanding

Neurotrophic Keratitis: Overview

Neurotrophic Keratitis (NK) is a degenerative corneal disease characterized by a reduction or absence of corneal sensation, leading to impaired healing and the risk of corneal damage. This condition is often a result of damage to the trigeminal nerve, which supplies sensation to the cornea. Causes of trigeminal nerve damage include viral infections such as herpes simplex or herpes zoster, surgical interventions, trauma, or systemic diseases like diabetes and multiple sclerosis. The lack of corneal sensation disrupts the normal healing processes and can result in persistent epithelial defects, corneal ulcers, and even perforation if not managed appropriately.

The progression of NK is typically divided into three stages. In the early stage, patients might experience minor symptoms such as dryness, discomfort, and mild visual disturbances due to superficial punctate keratopathy. As the disease advances to the moderate stage, there is an increased risk of persistent epithelial defects, leading to more significant visual impairment and discomfort. In the most severe stage, these defects can progress to corneal ulcers and perforations, posing a threat to vision and requiring more intensive therapeutic interventions. Diagnosis often involves clinical examination to assess corneal sensitivity, and imaging techniques may be used to evaluate the extent of corneal damage.

Treatment of Neurotrophic Keratitis aims to promote corneal healing and protect the cornea from further damage. Initial management includes lubricating eye drops or gels to maintain corneal moisture and reduce the risk of epithelial breakdown. In more advanced cases, therapeutic contact lenses, autologous serum eye drops, or amniotic membrane transplantation may be employed to support epithelial healing. Recently, the use of recombinant human nerve growth factor (rhNGF) has shown promise in promoting corneal nerve regeneration and healing. Surgical interventions, such as tarsorrhaphy or conjunctival flap surgery, may be necessary in cases of severe corneal ulceration or perforation. Overall, early diagnosis and tailored treatment strategies are crucial in managing NK and preventing long-term vision loss.

'Neurotrophic Keratitis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neurotrophic Keratitis pipeline landscape is provided which includes the disease overview and Neurotrophic Keratitis treatment guidelines. The assessment part of the report embraces, in depth Neurotrophic Keratitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurotrophic Keratitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neurotrophic Keratitis R&D. The therapies under development are focused on novel approaches to treat/improve Neurotrophic Keratitis.

Neurotrophic Keratitis Emerging Drugs Chapters

This segment of the Neurotrophic Keratitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neurotrophic Keratitis Emerging Drugs

RGN-259: ReGenTree, LLC

RGN-259 is an investigational ophthalmic solution developed by ReGenTree, LLC, aimed at treating neurotrophic keratitis (NK), a rare degenerative eye disease characterized by decreased corneal sensitivity and impaired healing. The active ingredient in RGN-259 is thymosin beta 4 (Tβ4), a regenerative protein known for promoting cell migration, reducing inflammation, and facilitating wound healing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Neurotrophic Keratitis.

Neurotrophic Keratitis: Therapeutic Assessment

This segment of the report provides insights about the different Neurotrophic Keratitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neurotrophic Keratitis

• There are approx. 4+ key companies which are developing the therapies for Neurotrophic Keratitis. The companies which have their Neurotrophic Keratitis drug candidates in the most advanced stage, i.e. Phase III include, ReGenTree, LLC.

Phases

The report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Neurotrophic Keratitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neurotrophic Keratitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neurotrophic Keratitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neurotrophic Keratitis drugs.

Neurotrophic Keratitis Report Insights

• Neurotrophic Keratitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Neurotrophic Keratitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Neurotrophic Keratitis drugs?
• How many Neurotrophic Keratitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neurotrophic Keratitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neurotrophic Keratitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neurotrophic Keratitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ReGenTree, LLC.

Claris Biotherapeutics, Inc.

Key Products

• RGN-259
• CSB-001

This product will be delivered within 2 business days.